미국의 말초신경자극기 시장 - 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 모달리티별, 접속성별, 용도별, 최종 용도별 부문 예측(2025-2033년)

Market Size & Trends:

The U.S. peripheral nerve stimulators market size was estimated at USD 105.14 million in 2024 and is projected to reach USD 253.36 million by 2033, growing at a CAGR of 10.43% from 2025 to 2033. The U.S. peripheral nerve stimulators industry is primarily driven by the rising prevalence of chronic pain conditions and increasing demand for minimally invasive, targeted pain management therapies, and the growing shift toward non-opioid therapies.

Growing awareness among healthcare providers and patients about the effectiveness of peripheral nerve stimulation in improving quality of life is fueling adoption. Technological advancements, including implantable systems, wearable stimulators, and enhanced programmable features, further propel market growth. The expansion of outpatient and ambulatory surgery centers, favorable reimbursement policies, and an aging population with higher surgical volumes contribute to the sustained momentum of the market.

Rising prevalence of chronic diseases continues to drive growth in the U.S. peripheral nerve stimulators industry, as patients with conditions such as diabetes, obesity, hypertension, asthma, and chronic pain increasingly require targeted, long-term pain management solutions. Peripheral nerve stimulators offer minimally invasive options to alleviate pain associated with these illnesses, improving patient outcomes and quality of life.

For instance, in April 2025, Health System Tracker highlighted that the U.S. has a higher rate of chronic diseases compared to peer nations, with over twice as many people affected by obesity and diabetes, 1.7 times more with asthma, and an overall higher burden of depression. This elevated prevalence of chronic conditions not only increases demand for advanced pain management therapies but also underscores the growing need for effective, clinically proven peripheral nerve stimulation solutions. According to the Pan American Health Organization's (PAHO) report, in July 2025, cardiovascular diseases led with 2.16 million deaths, followed by cancer (1.37 million), diabetes (over 420,000), and chronic respiratory conditions (more than 416,000). Suicide, the fourth leading cause of death among youth aged 15-29, claimed 100,760 lives.

U.S. Peripheral Nerve Stimulators Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. peripheral nerve stimulators market report based on product type, modality, connectivity, application, and end use:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Systems
• Implantable
• Non-implantable
  • Handheld
  • Others
• Wearables/Accessories
• Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Rechargeable
• Non-rechargeable
• Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
• Wired
• Wireless
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diabetic Peripheral Neuropathy Pain
• Chronic Musculoskeletal Pain
• Complex Regional Pain Syndrome (CRPS)
• Headache and Migraine Disorders
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Clinics
• Ambulatory Surgical Centers (ASCs)
• Physiotherapy/Rehabilitation Centers
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Modality
  • 1.2.3. Connectivity
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
  • 1.5.5. Information Analysis
  • 1.5.6. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Peripheral Nerve Stimulators Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High and rising prevalence of chronic pain
    • 3.2.1.2. Shift away from opioids toward non-opioid/interventional therapies
    • 3.2.1.3. Evidence and real-world adoption showing clinical benefit
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High device and procedure costs
    • 3.2.2.2. Technological limitations
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Outpatient centers and ambulatory surgery as key settings
    • 3.2.3.2. Aging population and comorbidities
  • 3.2.4. Market Challenges Analysis
    • 3.2.4.1. Device-related risks and complications
    • 3.2.4.2. Intense market competition
• 3.3. U.S. Peripheral Nerve Stimulators Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Peripheral Nerve Stimulators Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Peripheral Nerve Stimulators Market Product Type Movement Analysis
• 4.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. Systems
  • 4.4.1. Systems U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.1.1. Implantable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.1. Handheld
      • 4.4.1.1.2. Others
    • 4.4.1.2. Non-implantable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Wearables/Accessories
  • 4.5.1. Wearables/Accessories U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Peripheral Nerve Stimulators Market: Modality Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Peripheral Nerve Stimulators Market Modality Movement Analysis
• 5.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
• 5.4. Rechargeable
  • 5.4.1. Rechargeable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Non-rechargeable
  • 5.5.1. Non-rechargeable U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Peripheral Nerve Stimulators Market: Connectivity Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Peripheral Nerve Stimulators Market Connectivity Movement Analysis
• 6.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Connectivity, 2021 to 2033 (USD Million)
• 6.4. Wired
  • 6.4.1. Wired U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Wireless
  • 6.5.1. Wireless U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Peripheral Nerve Stimulators Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Peripheral Nerve Stimulators Market Connectivity Movement Analysis
• 7.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by Connectivity, 2021 to 2033 (USD Million)
• 7.4. Diabetic Peripheral Neuropathy Pain
  • 7.4.1. Diabetic Peripheral Neuropathy Pain U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Chronic Musculoskeletal Pain
  • 7.5.1. Chronic Musculoskeletal Pain U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Complex Regional Pain Syndrome (CRPS)
  • 7.6.1. Complex Regional Pain Syndrome (CRPS) U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Headache and Migraine Disorders
  • 7.7.1. Headache and Migraine Disorders U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Peripheral Nerve Stimulators Market: End-Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Peripheral Nerve Stimulators Market End-Use Movement Analysis
• 8.3. U.S. Peripheral Nerve Stimulators Market Size & Trend Analysis, by End-Use, 2021 to 2033 (USD Million)
• 8.4. Hospitals and Clinics
  • 8.4.1. Hospitals and Clinics U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Ambulatory Surgical Centers (ASCs)
  • 8.5.1. Ambulatory Surgical Centers (ASCs) U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Physiotherapy/Rehabilitation Centers
  • 8.6.1. Physiotherapy/Rehabilitation Centers U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others U.S. Peripheral Nerve Stimulators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. B. Braun Medical Inc.
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Modality Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Nalu Medical, Inc
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Modality Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Curonix LLC.
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Modality Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. SPR
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Modality Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Vygon
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Modality Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. AirLife
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Modality Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Neuspera Medical
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Modality Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Anesthesia Associates, Inc.
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Modality Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. AVNS
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Modality Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. Mercury Medical
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Modality Benchmarking
    • 9.2.10.4. Strategic Initiatives
  • 9.2.11. Medtronic
    • 9.2.11.1. Company Overview
    • 9.2.11.2. Financial Performance
    • 9.2.11.3. Modality Benchmarking
    • 9.2.11.4. Strategic Initiatives
  • 9.2.12. Boston Scientific Corporation
    • 9.2.12.1. Company Overview
    • 9.2.12.2. Financial Performance
    • 9.2.12.3. Modality Benchmarking
    • 9.2.12.4. Strategic Initiatives
  • 9.2.13. Abbott
    • 9.2.13.1. Company Overview
    • 9.2.13.2. Financial Performance
    • 9.2.13.3. Modality Benchmarking
    • 9.2.13.4. Strategic Initiatives
  • 9.2.14. Bioventus
    • 9.2.14.1. Company Overview
    • 9.2.14.2. Financial Performance
    • 9.2.14.3. Modality Benchmarking
    • 9.2.14.4. Strategic Initiatives
  • 9.2.15. Checkpoint Surgical Inc.
    • 9.2.15.1. Company Overview
    • 9.2.15.2. Financial Performance
    • 9.2.15.3. Modality Benchmarking
    • 9.2.15.4. Strategic Initiatives
  • 9.2.16. Nervonik, Inc
    • 9.2.16.1. Company Overview
    • 9.2.16.2. Financial Performance
    • 9.2.16.3. Modality Benchmarking
    • 9.2.16.4. Strategic Initiatives
• 9.3. Company Market Share Analysis, 2024
• 9.4. List of Other Key Market Players